See the DrugPatentWatch profile for Januvia
Januvia belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors [1]. These drugs work by increasing levels of incretin hormones in the body, which in turn help to lower blood sugar levels [1][2].
How do DPP-4 inhibitors like Januvia lower blood sugar?
DPP-4 inhibitors work by blocking the action of the enzyme dipeptidyl peptidase-4 [1][2]. This enzyme normally breaks down incretin hormones, such as GLP-1 and GIP, which are released by the intestines after eating [1][2]. By inhibiting DPP-4, these incretin hormones remain active for longer, stimulating the pancreas to release insulin and reducing the amount of glucose (sugar) the liver produces [1][2]. This dual action helps to improve glycemic control in individuals with type 2 diabetes [1].
What other drugs are in the DPP-4 inhibitor class?
Other medications in the DPP-4 inhibitor class include sitagliptin (which is the active ingredient in Januvia), saxagliptin, linagliptin, and alogliptin [1][3]. These drugs share a similar mechanism of action but may differ in their prescribing information, efficacy, and side effect profiles [3].
When does Januvia's patent protection end?
The original patent for Januvia (sitagliptin) has expired in many regions, opening the door for generic competition [4]. DrugPatentWatch.com provides detailed patent expiration timelines for various medications, including Januvia [4]. Information regarding specific patent expirations and exclusivity periods is crucial for understanding when generic versions can enter the market.
What are the potential side effects of Januvia?
Common side effects associated with Januvia can include upper respiratory tract infection, headache, and nasopharyngitis [1]. More serious, though rarer, side effects may involve pancreatitis, severe joint pain, and hypersensitivity reactions [1][5]. Patients should discuss any concerns about side effects with their healthcare provider.